Cargando…

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study

Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franchi, Francesco, Rollini, Fabiana, Kairouz, Victor, Rivas Rios, Jose, Rivas, Andrea, Agarwal, Malhar, Briceno, Maryuri, Wali, Mustafa, Nawaz, Ahmed, Silva, Gabriel, Shaikh, Zubair, Maaliki, Naji, Been, Latonya, Piraino, Jason, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Jennings, Lisa K., Bass, Theodore A., Angiolillo, Dominick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	CLINICAL RESEARCH
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978557/ https://www.ncbi.nlm.nih.gov/pubmed/31998847 http://dx.doi.org/10.1016/j.jacbts.2019.07.011

Ejemplares similares

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing
por: Franchi, Francesco, et al.
Publicado: (2020)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor
por: Angiolillo, Dominick J., et al.
Publicado: (2021)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Optimus Primed: Media Cultivation of Robot Mental Models and Social Judgments
por: Banks, Jaime
Publicado: (2020)

Optimizing the “Time to pregnancy” in women with multiple sclerosis: the OPTIMUS Delphi survey
por: Carbone, Luigi, et al.
Publicado: (2023)

Ahorro de energía eléctrica en sistemas optimus de iluminación artificial
por: Puig May, José Manuel
Publicado: (1993)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
por: Angiolillo, Dominick J., et al.
Publicado: (2011)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

CamOptimus: a tool for exploiting complex adaptive evolution to optimize experiments and processes in biotechnology
por: Cankorur-Cetinkaya, Ayca, et al.
Publicado: (2017)

Multicentre experience with Optimus balloon-expandable cobalt–chromium stents in congenital heart disease interventions
por: Haddad, Raymond N, et al.
Publicado: (2023)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
por: Murphy, Ravindhi, et al.
Publicado: (2023)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

Optimus Primer: A PCR enrichment primer design program for next-generation sequencing of human exonic regions
por: Brown, Andrew MK, et al.
Publicado: (2010)

A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study)
por: Kim, Eun Heui, et al.
Publicado: (2020)

Typical atrial flutter from blunt cardiac injury: an atypical cause
por: Maaliki, Naji, et al.
Publicado: (2021)

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations
por: Cho, Sung Won, et al.
Publicado: (2019)

An Integrated Care Strategy for Pre-schoolers with Suspected Developmental Disorders: The Optimus Co-design Project that has Made it to Regular Care
por: Sarkadi, Anna, et al.
Publicado: (2021)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Elusive Enterobacter cloacae causing pacemaker endocarditis
por: Maaliki, Naji, et al.
Publicado: (2021)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_28c997i4r9s4c08nn7umchakru